144 indexable Life Sciences companies headquartered in Taipei, Taiwan, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $443.7M across 19 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
SYNCELL
Developer of a microscopic system for the identification of proteins and biomarkers |
$15M | — | Series A | Series A Dec 2024 | 11 | 2020 | ↑ Active |
| 2 |
AP Biosciences
Recombinant antibody therapeutics discovery and development platform |
$38M | — | Public | Series D Jun 2024 | 31 | 2013 | — |
| 3 |
Anbogen Therapeutics
Developer of precision cancer therapeutics |
$12.5M | — | Series A | Series A Jan 2024 | — | 2019 | — |
| 4 |
APRINOIA
Developer of diagnostics and therapeutics for neurodegenerative disorders |
$51.1M | — | Series C | Series C Dec 2021 | 15 | 2015 | — |
| 5 |
Heroic-Faith
Provider of AI-based device for lung disease diagnosis |
$4M | — | Series A | Series A Aug 2023 | 20 | 2018 | — |
| 6 |
AnHorn Medicines
Developer of therapeutics for cancer, neurology, and age-related diseases |
$10M | — | Series A | Series A Apr 2023 | — | 2020 | — |
| 7 |
Elixiron
Developer of immunotherapy for cancer and immunological diseases |
$27M | — | Series A | Grant (prize money) Jul 2022 | 23 | 2016 | — |
| 8 |
TaiGen Biotechnology
Developer of therapeutics for infectious diseases and cancer |
$99M | — | Public | Series C Jan 2009 | 51 | 2001 | — |
| 9 |
Foresee Pharmaceuticals
Developer of injectables and NCEs for cancer and chronic diseases |
$32.5M | — | Public | Post IPO 2020 | 15 | 2011 | — |
| 10 |
ACT Genomics
Clinical and research services in genomics for cancer |
$20.5M | — | Acquired | Series B Sep 2020 | 300 | 2014 | — |
| 11 |
TaiMed Biologics
Developing antibodies and small molecule for the treatment and prevention of HIV infections |
$52M | — | Series B | Series B 2010 | 78 | 2007 | — |
| 12 |
Taiwan Liposome Company
Developer of nanomedicines for oncology, ophthalmology, osteoarthritis and pain management |
$27.3M | — | Public | Post IPO Oct 2019 | 112 | 1997 | — |
| 13 |
Amwise Diagnostics
Online platform for health information search |
$10M | — | Series B | Series B Feb 2020 | 25 | 2015 | — |
| 14 |
Senhwa Biosciences
Developer of small molecules for treating cancer |
$17M | — | Public | Series B Dec 2013 | 16 | 2012 | — |
| 15 |
Swissray Group
High-end medical imaging devices using Direct Digital Radiography |
$12.5M | — | Public | PE May 2004 | 92 | 1988 | — |
| 16 |
Bened Biomedical
Developer of probiotics for research and development |
$10M | — | Series A | Series A | — | 2015 | — |
| 17 |
Apollo Medical Optics
Developer of OCT-based medical imaging devices |
$3.4M | — | Series A | Series A Dec 2015 | — | 2014 | — |
| 18 |
HippoScreen
Developer of an EEG-based brain health diagnostic device for mental health |
$1.4M | — | Seed | Seed Dec 2019 | — | 2019 | — |
| 19 |
Medigen Vaccinology
Taiwanese biotech company that develops cell-based human vaccines for H5N1 and Enterovirus 71 |
$428.1K | — | Public | Unattributed Aug 2015 | 103 | 1999 | — |
| 20 |
MobioSense
Provider of a bio-molecule testing platform using system-on-a-chip technology |
— | — | Deadpooled | Grant (prize money) Dec 2016 | 3 | 2015 | — |
| 21 |
Synermore Biologics
R&D of new and biosimilar MAbs in the areas of oncology, infectious diseases, and immune disorders |
— | — | Seed | Seed 2016 | 90 | 2013 | — |
| 22 |
Taiwan Rui Biological Technology
Developing a small molecule therapy for cancer |
— | — | Public | Seed 2014 | 22 | 2011 | — |
| 23 |
3D Global Biotech
Developer of human tissues and organ reconstructed implants |
— | — | Public | — | 28 | 2014 | — |
| 24 |
Abnova
Proteins and bioreagents for life science research |
— | — | Public | — | 190 | 2002 | — |
| 25 |
AcuSolutions
Developer of medical imaging devices for intra-operative pathological diagnosis |
— | — | Funding Raised | — | — | 2009 | — |
| 26 |
Advagene Biopharma
Developer of immunomodulatory therapies for respiratory diseases and allergies |
— | — | Public | — | 6 | 2014 | — |
| 27 |
Allgenesis
Protein therapeutics for disorders in the areas of the CNS and Ophthalmology |
— | — | Unfunded | — | — | 2014 | — |
| 28 |
AmCad BioMed
Developer of CAD based ultrasound imaging systems |
— | — | Public | — | 34 | 2008 | — |
| 29 |
Amed
Wound Dressing Hydrogel for wound care application |
— | — | Deadpooled | — | — | 2009 | — |
| 30 |
APEX
Respiratory Devices and Wound Management Products |
— | — | Public | — | 4 | 1990 | — |
| 31 |
Astron Medtech
Developer of minimally invasive surgical device for orthopedic treatment |
— | — | Unfunded | — | — | 2021 | — |
| 32 |
ATP BioPharm
Developer of small molecule therapy for cancer and neural degenerative diseases |
— | — | Deadpooled | — | — | 2019 | — |
| 33 |
AventaCell BioMedical
Bioreagents for cell culture and tissue engineering |
— | — | Unfunded | — | — | 2015 | — |
| 34 |
BAUI Biotech
A range of spinal implants |
— | — | Unfunded | — | — | 2009 | — |
| 35 |
BenQ
Provider of medical equipment and consumables for hospital operation system |
— | — | Public | — | — | 1989 | — |
| 36 |
Biocommander
Immunology reagents |
— | — | Unfunded | — | — | 2006 | — |
| 37 |
Biocontrol Gene Vaccine
Developer of drugs to treat cancer and infectious diseases using immunotherapies |
— | — | Public | — | 61 | 2012 | — |
| 38 |
BioGend Therapeutics
Developer of regenerative medicine for bone and cartilage repair |
— | — | Funding Raised | — | — | 2016 | — |
| 39 |
BioMab
Immune-based diagnostics and therapeutics |
— | — | Unfunded | — | — | 2015 | — |
| 40 |
BRAXX Biotech
Developer of radiation therapy device for esophageal cancer |
— | — | Unfunded | — | — | 2016 | — |
| 41 |
Calgent Biotechnology
Developer of therapeutics for cancer and immunological disorders |
— | — | Unfunded | — | — | 2019 | — |
| 42 |
Capstone Biotek
Provider of reagents for the life science and regenerative medicine research organizations |
— | — | Deadpooled | — | — | 2017 | — |
| 43 |
center ventures
Center Ventures is a pharmaceutical company. |
— | — | Public | — | 182 | 1959 | — |
| 44 |
Chin Bone Technique
Fixation devices for osteoporosis and soft tissue repair implant |
— | — | Unfunded | — | — | 2009 | — |
| 45 |
CHO Pharma
Biopharma specializing in developing novel products based on proprietary glycan engineering technologies |
— | — | Public | — | 40 | 2013 | — |
| 46 |
COMDEK
Devices for the diagnostic and homecare applications |
— | — | Unfunded | — | — | 1985 | — |
| 47 |
Cytena Bioprocess Solutions
Developer of single-use microbioreactors |
— | — | Funding Raised | — | 32 | 2018 | — |
| 48 |
Cyto Pharma
Developing protein therapeutics against viral diseases and cancer |
— | — | Unfunded | — | — | 2003 | — |
| 49 |
DAOPiN
Provider of bioinformatics products and analysis services |
— | — | Deadpooled | — | — | 2018 | — |
| 50 |
Dino
Manufacturer of portable digital microscopes for consumer and professional use |
— | — | Unfunded | — | — | 2007 | — |
Developer of a microscopic system for the identification of proteins and biomarkers. By using proprietary optoproteomics technology it has developed Microscoop that is capable of identifying proteins. It uses automated AI-based recognition algorithms and photochemical labeling reagents, to identify and quantify novel proteins for discovery research and disease mechanism studies.
AP Biosciences is a biotech company that has a therapeutic antibody discovery platform which can be used to generate antibodies against a broad range of target proteins including proteins, peptides, whole cells and haptens. The company's discovery pipeline covers screening/discovery, functionalization, in vitro and in vivo characterization and expression cell line generation. Their platform's central asset is the Omn
Developer of precision cancer therapeutics. It offers drug candidates ABT-101 a tyrosine kinase inhibitor targeting HER2 Exon20 insertion from solid tumor cancer, ABT-201 a KRAS inhibitor targeting non-small cell lung cancer, and ABT-301 a small molecule histone deacetylase inhibitor (HDACi).
Developer of diagnostics and therapeutics for neurodegenerative disorders. The company focuses on the development of tau, alpha-synuclein, and other proteins that target neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. The company's lead candidate is APNmAb005 a humanized anti-tau antibody specifically targeting human tau aggregates found in tau-related diseases including Alzheimer's Disease.
Heroic is a provider of AI-based devices for lung disease diagnosis. The solution offers by the company is used in remote lung sound monitor and in COPD (Chronic Obstructive Pulmonary Disease). The device is also used or the ICU patients as wells as for the COVID-19 patients. The AI-based technology is used to monitor the respiratory rate for the different pathological conditions as respiratory stenosis, obstruction,
Developer of therapeutics for cancer, neurology, and age-related diseases. It offers protein degradation drugs which include AH-001 for the treatment of androgenetic alopecia. It also provides drugs for prostate cancer, lymphoma, pancreatic, and colorectal cancer, neurodegenerative disease, and others.
Developer of immunotherapy for cancer and immunological diseases. The company's drug candidates include EI-1071 for Alzheimer's disease, tenosynovial giant cell tumors, EI-001 for vitiligo, and others for cancer. The platform has developed the proprietary human single B cell cloning technology and anti-cytokine monoclonal antibodies for targeting the immunosuppressive tumor for cancer treatment.
Developer of therapeutics for infectious diseases and cancer. The company focuses on the discovery, development, and commercialization of therapeutics to treat cancers, infectious diseases and diabetic complications. It markets Nemonoxacin, a drug-resistant anti-infection drug for community-acquired pneumonia. It is developing Burixafor (TG-0054) which is a potent and selective CXCR4 chemokine receptor antagonist.
Foresee Pharmaceuticals develops injectables and NCEs for cancer, endocrine disorders, and inflammatory diseases. Its stabilized injectable formulation platform is primarily a controlled release drug delivery platform for small molecules, peptides, and other bioactive. Its lead candidate is in phase III trials for prostate cancer, and another candidate in phase II trials for COPD and asthma. In addition, it has other
ACT Genomics offers clinical and research services in genomics for cancer. Its clinical offerings include NGS panels for auto-immune disease (ACTImmune), colon cancer (ACTColon), gastric cancer (ACTGastric) and breast cancer (ACTBreast). It also provides pharmacogenomic panels ACTDrug and ACTOnco that help physicians tailor therapies according to the patient's genotype. In addition, the company provides custom genomi
TaiMed Biologics is a biotechnology company that develops a monoclonal Antibody (mAb) therapeutics for HIV. The company's lead product, Ibalizumab (TMB-355), won the FDA's breakthrough drug title for HIV. Ibalizumab works by barring the virus' entry into cells by hitting the CD4 receptor, a primary mechanism in the spread of infection. The company recently announced schedule for phase 3 trials for its anti-HIV drug c
TLC Bio is a is a developer of nanomedicines for oncology, ophthalmology, osteoarthritis, and pain management. It uses proprietary lipid-based technologies to develop new formulations (micelles and nanoparticles). It is developing drugs in Oncology, Peripheral Arterial Disease, Ophthalmology, Arthritis, and Anesthetics.
_1532515568579.png){kind=logo}
CDIB Capital Group
YFY
Diamond Biofund
Darwin Venture Management
Harbinger Venture Capital
Maxpro Ventures
Taiwania Capital
National Development Fund
Taian Biotechnology
WI Harper Group
Blackmarble
CDIB Capital
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-20.
_1530687280280.png){kind=logo}
_1560235902098.jpeg){kind=logo}
_1576845386159.png){kind=logo}
_1530860621470.png){kind=logo}
_1574749846686.png){kind=logo}
_1523945937561.png){kind=logo}
_1564549907993.png){kind=logo}
_1582012509394.png){kind=logo}
.png1507102290742){kind=logo}
_1530591972453.png){kind=logo}
